Developed Countries Sample Clauses

Developed Countries. In terms of stock selection a value approach is used Value screens give simplicity, consistency and discipline to our work. Each stock is ranked relative to the others within its own market on each of six variables: PE ratio ] Price to cash flow ratio ] Value Screens Price to book value ] Dividend yield ] Cash flow to total liabilities ratio and ] Fundamental Screens EPS growth Each variable except book value and total liabilities is based on prospective numbers. We use consensus forecasts. The six factors are then combined into one composite relative value ranking (RVR). The current RVR is compared to its historic range and an extreme RVR triggers the active part of the process. Having used the value screens to determined our interest in a given stock, fundamental research focuses on the reasons why the stock may now be trading cheaply or expensively. Our fundamental work thus focuses on key issues rather than a mass of detail. We investigate company strategy, industry competition, management changes and financial data. If we can find no justification for the RVR we have ascribed, the stock becomes a candidate for purchase or sale. The third stage of the value active process uses sentiment indicators to assist with the timing of buy/sell decisions. One of the side effects of value screening is that it gives no indication of the timing involved before the market recognizes the value signaled by the screen. Sentiment indicators have been tailored for each market; they are a mixture of moving average and momentum indicators. Importantly, the value screening creates equally strong sell signals and our sell disciplines are rigorous. Any stock which has an RVR which indicates it should be sold can only then be held after a process of per review in which the portfolio manager justifies the fundamentals. The head of international makes the ultimate decision. Sector weightings in each country portfolio vary from index as a result of the stock ranking process, but are reviewed as part of overall portfolio tracking error.
AutoNDA by SimpleDocs
Developed Countries. The top group in the comprehensive but mutually exclusive hierarchy of developed countries, Developing countries and Least developed countries. It includes the market- oriented economies of the mainly democratic nations in the OECD, Bermuda, Israel, South Africa, and the European mini-states. This group is also known as the First World, high-income countries, the North, industrial countries. As of 2000, 1.2 billion people lived in developed countries. DDA - Doha Development Agenda: On 14 November 2001 the 142 members (at that time) of the WTO agreed at a meeting in Doha (Qatar) to launch a new round of world trade talks. This is the ninth round of world trade negotiations. Like previous rounds this one seeks to further liberalise trade. This round will also review trade rules and make sure that its conclusion strengthens the capacity of developing countries to benefit fully from the resulting boost in international trade. For this reason it has been called the Doha Development Agenda (DDA). The negotiations are scheduled to last three years - until January 2005. DDR – Differentiated Discount Rate is a discount rate based on the Commercial Interest Reference Rate (CIRR) and used to determine the concessionality level of a loan.
Developed Countries. The Commission shall assess the operations supported by the EFSD guarantee against the eligibility criteria established in Article 8(1) and 8(2), where possible drawing on eligible counterparts’ existing result measurement systems. It shall publish the result of its assessment for each investment window on an annual basis.

Related to Developed Countries

  • New Countries The Fund shall be responsible for informing the Custodian sufficiently in advance of a proposed investment which is to be held in a country in which no Subcustodian is authorized to act in order that the Custodian shall, if it deems appropriate to do so, have sufficient time to establish a subcustodial arrangement in accordance herewith. In the event, the Custodian is unable to establish such arrangements prior to the time the investment is to be acquired, the Custodian is authorized to designate at its discretion a local safekeeping agent, and the use of the local safekeeping agent shall be at the sole risk of the Fund, and accordingly the Custodian shall be responsible to the Fund for the actions of such agent if and only to the extent the Custodian shall have recovered from such agent for any damages caused the Fund by such agent.

  • Territory 43.1 This Agreement applies to the territory in which Verizon operates as an Incumbent Local Exchange Carrier in the Commonwealth of Pennsylvania. Verizon shall be obligated to provide Services under this Agreement only within this territory.

  • Competing Products The provisions of Section 21 are set forth on attached Exhibit H and are incorporated in this Section 21 by this reference.

  • Combination Products If a LICENSED PRODUCT , DISCOVERY PRODUCT and/or THERAPEUTIC PROUCT is sold to any third party in combination with other products, devices, components or materials that are capable of being sold separately and are not subject to royalties hereunder (“OTHER PRODUCTS,” with the combination of products being referred to as “COMBINATION PRODUCTS” and the Other Product and Licensed Product in such Combination Product being referred to as the “COMPONENTS”), the NET SALES of such LICENSED PRODUCT, DISCOVERY PRODUCT and/or THERAPEUTIC PRODUCT included in such COMBINATION PRODUCT shall be calculated by multiplying the NET SALES of the COMBINATION PRODUCT by the fraction A/(A+B), where A is the average NET SALES price of such LICENSED PRODUCT, DISCOVERY PRODUCT and/or THERAPEUTIC PRODUCT in the relevant country, as sold separately, and B is the total average NET SALES price of all OTHER PRODUCTS in the COMBINATION PRODUCT in the relevant country, as sold separately. If, in any country, any COMPONENT is not sold separately, NET SALES for royalty determination shall be determined by the formula [C / (C+D)], where C is the aggregate average fully absorbed cost of the LICENSED PRODUCT, DISCOVERY PRODUCT and/or THERAPEUTIC PRODUCT components during the prior Royalty Period and D is the aggregate average fully absorbed cost of the other essential functional components during the prior Royalty Period, with such costs being determined in accordance with generally accepted accounting principles. To the extent that any SUBLICENSE INCOME relates to a COMBINATION PRODUCT or is otherwise calculated based on the value of one or more licenses or intellectual property rights held by the COMPANY, an AFFILIATE or SUBLICENSEE, COMPANY shall determine in good faith and report to THE PARTIES the share of such payments reasonably attributable to COMPANY’s or such AFFILIATE’s sublicense of the rights granted hereunder, based upon their relative importance and proprietary protection, which portion shall be the SUBLICENSE INCOME. THE PARTIES shall have the right to dispute such sharing determination in accordance with the dispute provisions of the AGREEMENT.

  • Commercialization Efforts The RECIPIENT shall, including whether through its own efforts or the efforts of a licensee under a License Agreement allowed by the terms of this Attachment, use diligent and commercially reasonable efforts to commercialize at least one Commercial Product or Commercial Service or otherwise bring to practical application the Project Results in accordance with the commercial development plan submitted with the Application and including any changes to such commercial development plan in accordance with Section D3.01. For the avoidance of doubt, partnering or licensing activities shall be considered to be efforts to commercialize.

  • Licensed Products Lessee will obtain no title to Licensed Products which will at all times remain the property of the owner of the Licensed Products. A license from the owner may be required and it is Lessee's responsibility to obtain any required license before the use of the Licensed Products. Lessee agrees to treat the Licensed Products as confidential information of the owner, to observe all copyright restrictions, and not to reproduce or sell the Licensed Products.

  • Development Activities The Development activities referred to in item “b” of paragraph 3.1 include: studies and projects of implementation of the Production facilities; drilling and completion of the Producing and injection xxxxx; and installation of equipment and vessels for extraction, collection, Treatment, storage, and transfer of Oil and Gas. The installation referred to in item “c” includes, but is not limited to, offshore platforms, pipelines, Oil and Gas Treatment plants, equipment and facilities for measurement of the inspected Production, wellhead equipment, production pipes, flow lines, tanks, and other facilities exclusively intended for extraction, as well as oil and gas pipelines for Production Outflow and their respective compressor and pumping stations.

  • Commercialization License Subject to the terms of this Agreement, including without limitation Section 2.2 and Theravance's Co-Promotion rights in Section 5.3.2, Theravance hereby grants to GSK, and GSK accepts, an exclusive license under the Theravance Patents and Theravance Know-How to make, have made, use, sell, offer for sale and import Alliance Products in the Territory.

  • New Products You agree to comply with NASD Notice to Members 5-26 recommending best practices for reviewing new products.

  • EXTRA-CURRICULAR ACTIVITIES 1. In this agreement, extra-curricular programs and activities include all those that are beyond the provincially prescribed and locally determined curricula of the school.

Time is Money Join Law Insider Premium to draft better contracts faster.